Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 410 in KRAS-altered Advanced Solid Tumors (Japan Phase 1/1b)
jRCT2041250127Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of AMG 410 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 1 more (4 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
AMG 410
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2041250127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250127.